FDA
-
-
-
-
-
-
-
Edwards Lifesciences provides 2026 financial guidance at investor conference
-
-
-
-
-
-
-
Pulnovo Medical Names Dr. Francis Duhay as Global Chief Medical Officer
-
-
-
-
-
-
-
Edwards TAVR Receives FDA Approval for Patients With Asymptomatic Severe Aortic Stenosis
-
-
-
-
-
-
-
Stifel Upgrades Edwards Lifesciences (EW) to Buy
-
-
-
-
-
-
-
Five-Year Data Show Excellent Outcomes for Female and Small Annulus Patients With Edwards TAVR
-
-
-
-
-
-
-
Citi Downgrades Edwards Lifesciences (EW) to Neutral, 'Near term still transitional'
-
-
-
-
-
-
-
Edwards Lifesciences cut to equal weight at Wells Fargo on limited upside to TAVR market growth
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

